• 1
    Medsger, T. A., Jr., Systemic sclerosis (scleroderma): clinical aspects. In Koopman, W. J. (Ed.) Arthritis and Allied Conditions ,14th edn. Lippincott Williams & Wilkins, Philadelphia 2001, pp 15901624.
  • 2
    LeRoy, E. C., Increased collagen synthesis by scleroderma skin fibroblasts in vitro. A possible defect in the regulation or activation of the scleroderma fibroblasts. J. Clin. Invest. 1974. 54: 880889.
  • 3
    Rodnan, G. P., Lipinski, E. and Luksick, J., Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum. 1979. 22: 130140.
  • 4
    Kulozik, M., Hogg, A., Lankat-Buttgereit, B. and Krieg, T., Co-localization of transforming growth factor β2 with α1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J. Clin. Invest. 1990. 86: 917922.
  • 5
    Varga, J. and Jimenez, S. A., Pathogenesis of scleroderma: cellular aspects. In Clements, P. J. and Furst, D. E. (Eds.) Systemic Sclerosis. Williams & Wilkins, Philadelphia 1996, pp 123152.
  • 6
    Feghali, C. A., Bost, K. L., Boulware, D. W. and Levy, L. S., Mechanisms of pathogenesis in scleroderma. I. Overexpression of interleukin-6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J. Rheumatol. 1992. 19: 12071211.
  • 7
    Igarashi, A., Nashiro, K., Kikuchi, K., Sato, S., Ihn, H., Grotendorst, G. R. and Takehara, K., Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J. Invest. Dermatol. 1995. 105: 280284.
  • 8
    Kurasawa, K., Hirose, K., Sano, H., Endo, H., Shinkai, H., Nawata, Y., Takabayashi, K. and Iwamoto, I., Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum. 2000. 43: 24552463.
  • 9
    Ihn, H., Yamane, K., Kubo, M. and Tamaki, K., Blockade of endogenoustransforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum. 2001. 44: 474480.
  • 10
    Giacomelli, R., Matucci-Cerinic, M., Cipriani, P., Ghersetich, I., Lattanzio, R., Pavan, A., Pignone, A., Cagnoni, M. L., Lotti, T. and Tonietti, G., Circulating Vdelta+ T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum. 1998. 41: 327334.
  • 11
    Sakamoto, A., Sumida, T., Maeda, T., Itoh, M., Asai, T., Takahashi, H., Yoshida, S., Koike, T., Tomioka, H. and Yoshida, S., T cell receptor V beta repertoire of double-negative alpha/beta T cells in patients with systemic sclerosis. Arthritis Rheum. 1992. 35: 944948.
  • 12
    Sakkas, L. I., Xu, B., Arlett, C. M., Lu, S., Jimenez, S. A. and Platsoucas, C. D., Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J. Immunol. 2002. 168: 36493659.
  • 13
    Wells, A. U., Lorimer, S., Majumdar, S., Harrison, N. K., Corrin, B., Black, C. M., Jeffery, P. K. and du Bois, R. M., Fibrosing alveolitisin systemic sclerosis: increase in memory T cells in lung interstitium. Eur. Respir. J. 1995. 8: 266271.
  • 14
    Trotta, F., Biagini, G., Cenacchi, G., Ballardini, G., Varotti, C., Passarini, B., Garbisa, S., Faccani, G., Bianchi, F. B. and Govoni, E., Microvascular changes in progressive systemic sclerosis: immunohistochemical and ultrastructural study. Clin. Exp. Rheumatol. 1984. 2: 209215.
  • 15
    Roumm, A. D., Whiteside, T. L., Medsger, T. A., Jr. and Rodnan, G. P., Lymphocytes in the skin of patients with progressive systemic sclerosis. Arthritis Rheum. 1984. 27: 645653.
  • 16
    Banchereau, J., Bazan, F., Blanchard, D., Briere, F., Galizzi, J. P., van Kooten, C., Liu, Y. J., Rousset, F. and Saekand, S., The CD40 antigen and its ligand. Annu. Rev. Immunol. 1994. 12: 881922.
  • 17
    Brouty-Boye, D., Pottin-Clemenceau, C., Doucet, C., Jasmin, C. and Azzarone, B., Chemokines and CD40 expression in human fibroblasts. Eur. J. Immunol. 2000. 30: 914919.
  • 18
    Fries, K. M., Sempowski, G. D., Gaspari, A. A., Blieden, T., Looney, R. J. and Phipps, R. P., CD40 expression by human fibroblasts. Clin. Immunol. Immunopathol. 1995. 77: 4251.
  • 19
    Companjen, A. R., van der Wel, L. I., Boon, L., Prens, E. P. and Laman, J. D., CD40 ligation–induced cytokine production in human skin explants is partly mediated via IL-1 . Int. Immunol. 2002. 14: 669676.
  • 20
    Wassenaar, A., Verschoor, T., Kievits, F., Den Hartog, M. T., Kapsenberg, M. L., Everts, V. and Snijders, A., CD40 engagement modulates the production of matrix metalloproteinases by gingival fibroblasts. Clin. Exp. Immunol. 1999. 115: 161167.
  • 21
    King, A. E., Kelly, R. W., Critchley, H. O. D., Malmstrom, A., Sennstrom, M. and Phipps, R. P., CD40 expression in uterine tissues: a key regulator of cytokine expression by fibroblasts. J. Clin. Endocrinol. MeTable  2001. 86: 405412.
  • 22
    Hawkins, R. A., Claman, H. N., Clark, R. A. and Steigerwald, J. C., Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann. Intern. Med. 1985. 102: 182186.
  • 23
    Valentini, G., Romano, M. F., Naclerio, C., Bisogni, R., Lamberti, A., Turco, M. C. and Venuta, S., Increased expression of CD40 ligand in activated CD4+ T lymphocytes of systemic sclerosis patients. J. Autoimmun 2000. 15: 6166.
  • 24
    Kadono, T., Kikuchi, K., Ihn, H., Takehara, K. and Tamaki, K., Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J. Rheumatol. 1998. 25: 296301.
  • 25
    Yamamoto, T., Eckes, B. and Krieg, T., High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur. J. Immunol. 2001. 31: 29362941.
  • 26
    June, C. H., Bluestone, J. A., Nadler, L. M. and Thompson, C. B., The B7 and CD28 receptor families. Immunol. Today 1994. 15: 321331.
  • 27
    Laning, J. C., Deluca, J. E., Isaacs, C. M. and Hardin-Young, J., In vitro analysis of CD40-CD154 and CD28-CD80/86 interactions in the primary T cell response to allogeneic "nonprofessional" antigen presenting cells. Transplantation 2001.71: 14671474.
  • 28
    Sime, P. J. and O'Reilly, K. M. A., Fibrosis of the lung and other tissue: new concepts in pathogenesis and treatment. Clin. Immunol. 2001. 99: 308319.
  • 29
    Liu, M. F., Chao, S. C., Wang, C. R. and Lei, H. Y., Expression of CD40 and CD40 ligand among cell populations within rheumatoid synovial compartment. Autoimmunity 2001. 34: 107113.
  • 30
    Sugiura, T., Kawaguchi, Y., Harigai, M., Takagi, K., Ohta, S., Fukasawa, C., Hara, M. and Kamatani, N., Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction on IL-6, IL-8, IL-15, and MCP-1 production. J. Immunol. 2000. 164: 65936600.
  • 31
    Zhang-Hoover, J., Sutton, A. and Stein-Streilein, S., CD40/CD40 ligand interactions are critical for elicitation of autoimmune-mediated fibrosis in the lung. J. Immunol. 2001. 166: 35563563.
  • 32
    Girvin, A. M., Dal Canto, M. C. and Miller, S. D., CD40/CD40L interaction is essential for the induction of EAE in the absence of CD28-mediated co-stimulation. J. Autoimmun. 2002. 18: 8394.
  • 33
    Mohan, C., Shi, Y., Laman, J. D. and Datta, S. K., Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 1995. 154: 14701480.
  • 34
    Early, G. S., Zhao, W. and Burns, C. M., Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black × New Zealand white mice: response correlates with the absence of an anti-antibody response. J. Immunol. 1996. 157: 31593164.
  • 35
    Xu, H., Tadaki, D. K., Elster, E. A., Burkly, L. C., Berning, J. D., Cruzata, F., Kampen, R. L., Montgomery, S. P., Patterson, N. B., Harlan, D. M. and Kirk, A. D., Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. Transplantation 2002. 74: 940943.
  • 36
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980. 23: 581590.
  • 37
    LeRoy, E. C., Black, C., Fleischmajer, R., Jablonska, S., Krieg, T., Medsger, T. A., Jr., Rowell, N. and Wollheim, F., Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 1988. 15: 202205.
  • 38
    Clements, P. J., Lachenbruch, P., Seibold, J. R., et al., Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J. Rheumatol. 1995. 22: 12811285.
  • 39
    Kawaguchi, Y., Suzuki, K., Hara, M., Hidaka, T., Ishizuka, T., Kawagoe, M. and Nakamura, H., Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann. Rheum. Dis. 1994. 53: 506510.